PE20080380A1 - Sales de 2-(metiloxi)-n-[2-metil-1-fenil-2-(1-pirrolidinil)propil]-4,6-bis(trifluorometil)benzamida que tienen actividad en el transportador glyt1 - Google Patents

Sales de 2-(metiloxi)-n-[2-metil-1-fenil-2-(1-pirrolidinil)propil]-4,6-bis(trifluorometil)benzamida que tienen actividad en el transportador glyt1

Info

Publication number
PE20080380A1
PE20080380A1 PE2007000782A PE2007000782A PE20080380A1 PE 20080380 A1 PE20080380 A1 PE 20080380A1 PE 2007000782 A PE2007000782 A PE 2007000782A PE 2007000782 A PE2007000782 A PE 2007000782A PE 20080380 A1 PE20080380 A1 PE 20080380A1
Authority
PE
Peru
Prior art keywords
methyloxy
pyrrolidinyl
trifluoromethyl
propyl
bis
Prior art date
Application number
PE2007000782A
Other languages
English (en)
Inventor
Claire Louise Anderton
David Clapham
Trevor Raymond Keel
Leanda Jane Kindon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080380A1 publication Critical patent/PE20080380A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA SAL DE 2-(METILOXI)-N-[2-METIL-1-FENIL-2-(1-PIRROLIDINIL)PROPIL]-4,6-BIS(TRIFLUOROMETIL)BENZAMIDA. SON SALES PREFERIDAS: SUCCINATO, NAPADISILATO, MONOSUCCINATO, HEMINAPADISILATO. TAMBIEN ESTA REFERIDA A LAS SALES EN FORMA CRISTALINA Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE EL TRANSPORTADOR DE GlyT1 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS PSIQUIATRICOS TALES COMO DEMENCIA, DEPRESION, ENTRE OTROS, TRASTORNOS NEUROLOGICOS, ENTRE OTROS
PE2007000782A 2006-06-22 2007-06-20 Sales de 2-(metiloxi)-n-[2-metil-1-fenil-2-(1-pirrolidinil)propil]-4,6-bis(trifluorometil)benzamida que tienen actividad en el transportador glyt1 PE20080380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612420.0A GB0612420D0 (en) 2006-06-22 2006-06-22 Compounds

Publications (1)

Publication Number Publication Date
PE20080380A1 true PE20080380A1 (es) 2008-05-31

Family

ID=36803732

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000782A PE20080380A1 (es) 2006-06-22 2007-06-20 Sales de 2-(metiloxi)-n-[2-metil-1-fenil-2-(1-pirrolidinil)propil]-4,6-bis(trifluorometil)benzamida que tienen actividad en el transportador glyt1

Country Status (23)

Country Link
US (1) US20080070973A1 (es)
EP (1) EP2041082B1 (es)
JP (1) JP2009541261A (es)
KR (1) KR20090019847A (es)
CN (1) CN101506156A (es)
AR (1) AR061554A1 (es)
AT (1) ATE444288T1 (es)
AU (1) AU2007263058A1 (es)
BR (1) BRPI0713311A2 (es)
CA (1) CA2655399A1 (es)
CL (1) CL2007001808A1 (es)
CR (1) CR10498A (es)
DE (1) DE602007002642D1 (es)
EA (1) EA200970044A1 (es)
ES (1) ES2333918T3 (es)
GB (1) GB0612420D0 (es)
IL (1) IL195633A0 (es)
MA (1) MA30522B1 (es)
NO (1) NO20085412L (es)
PE (1) PE20080380A1 (es)
TW (1) TW200817322A (es)
WO (1) WO2007147831A1 (es)
ZA (1) ZA200810009B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
JP2010530397A (ja) * 2007-06-20 2010-09-09 グラクソ グループ リミテッド アミド形成の改善方法
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
ES2928785T3 (es) 2017-10-13 2022-11-22 Treeway Tw001 B V Sal de edaravona

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746959A (en) * 1953-06-02 1956-05-22 American Home Prod Diphenylethylenediamine-penicillin salt
US3145209A (en) * 1961-07-31 1964-08-18 Olin Mathieson Substituted aminophenyl-ethylamine derivatives
NZ237443A (en) * 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina

Also Published As

Publication number Publication date
CL2007001808A1 (es) 2008-01-18
DE602007002642D1 (de) 2009-11-12
IL195633A0 (en) 2009-09-01
ES2333918T3 (es) 2010-03-02
AR061554A1 (es) 2008-09-03
BRPI0713311A2 (pt) 2012-03-06
NO20085412L (no) 2009-01-22
CA2655399A1 (en) 2007-12-27
WO2007147831A1 (en) 2007-12-27
EA200970044A1 (ru) 2009-04-28
EP2041082A1 (en) 2009-04-01
EP2041082B1 (en) 2009-09-30
AU2007263058A1 (en) 2007-12-27
TW200817322A (en) 2008-04-16
GB0612420D0 (en) 2006-08-02
ATE444288T1 (de) 2009-10-15
JP2009541261A (ja) 2009-11-26
CN101506156A (zh) 2009-08-12
KR20090019847A (ko) 2009-02-25
CR10498A (es) 2009-03-20
US20080070973A1 (en) 2008-03-20
ZA200810009B (en) 2009-11-25
MA30522B1 (fr) 2009-06-01

Similar Documents

Publication Publication Date Title
CR11095A (es) Compuestos amino-heterociclicos
CY1122565T1 (el) Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης
CR9462A (es) Inhibidores de la dipeptidil peptidasa-iv
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
UY32391A (es) Compuestos amino-heterocíclicos
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
ECSP12012026A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
DOP2005000040A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
BRPI0820505A2 (pt) Lipossomos termossensíveis que contêm agentes terapêuticos
DOP2006000141A (es) Derivados de oxindol
UY31243A1 (es) Compuestos de 2-aza-biciclo[2.2.2]octano y usos para los mismos
UY29766A1 (es) Formas cristalinas delta y épsilon de mesilato de imatinib
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
AR065798A1 (es) Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina
PE20080380A1 (es) Sales de 2-(metiloxi)-n-[2-metil-1-fenil-2-(1-pirrolidinil)propil]-4,6-bis(trifluorometil)benzamida que tienen actividad en el transportador glyt1
SV2006002073A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos ref. pc 32080a
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
NI201100051A (es) Sales de n - [ 6 - ( cis - 2, 6 - dimetil - morfolin - 4 - il ) - piridin - 3 - il ] - 2 - metil - 4' - ( trifluoro - metoxi ) - [ 1, 1' - bifenil] - 3 - carboxamida.
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
FR2881349B1 (fr) Nouvelle utilisation des galactomannanes en tant qu'agent actif en cosmetique.
ECSP088761A (es) Nuevas combinaciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
UY34647A (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
FD Application declared void or lapsed